Navigation Links
Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
Date:3/30/2009

d for re-election this year. The Company greatly appreciates Mr. Greene's and Ms. Graham's many years of dedicated service to build and grow the Company, both as directors and former leaders of Amylin.

Stockholders may review more detailed biographies of all Amylin's nominees in the Company's preliminary proxy statement filed today with the Securities and Exchange Commission.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin that involve risks and uncertainties. The Company's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks and uncertainties that are described in the Company's recently filed annual report on Form 10-K. Amylin disclaims any obligation to update these forward-looking statements.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin will be filing a proxy statement with the Securities and Exchange Commission ("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
2. Amylin Pharmaceuticals Reports 2008 Financial Results
3. Amylin Pharmaceuticals to Webcast Year-End Results
4. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
5. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
6. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
7. Lilly and Amylin Set Date and Time for Conference Call
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Amylin Pharmaceuticals Reports First Quarter Financial Results
10. Amylin Pharmaceuticals Reports 2007 Financial Results
11. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a gymnastics ... 12 years of age that offers everything from gymnastics, dance, ... Camps, is now under new ownership. , Kevin Berry comes ... over six years at The Little Gym of Bellaire in ... has over ten years of experience working with children, including ...
(Date:7/13/2014)... 2014 Max International has ... will be the featured guest at its Charity Exhibition ... Rico. Attendees will learn about Max’s health products ... exhibition basketball games and perform in a 3 point ... health- and energy-boosting supplements , has recently announced former ...
(Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 A ... Wright & Schulte LLC to provide consumers with the ... sometimes accompany use of the blood-thinning medication, as well ... pending in courts around the country. The law ... who may have suffered from life-threatening internal bleeding and ...
(Date:7/13/2014)... Ann Arbor, MI (PRWEB) July 13, 2014 ... online learning program he has just launched at http://www.HealthYourself101.com ... management of visceral obesity. , Power has set out ... and its ill effects that’s actually – dare we say ... , “The program,” says Power, “aims to engage the remote ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... to treat injury, stroke and even Alzheimer,s, experts say , , ... study involving mice suggests the brain,s own stem cells may ... These neural stem cells work by protecting existing cells and ... the University of California, Irvine, were able to bring the ...
... As the seventh leading cause of cancer death worldwide, ... ethnic group and gender. Esophageal cancer is thought to ... interact with the host genome. Researchers have long been ... been conducted on gene-environment interaction and gene polymorphisms for ...
... remove part or all of the colon (colectomy) for people ... researchers in a study published on bmj.com today. ... of the intestine and includes ulcerative colitis and Crohns disease. ... are affected and many people will require colectomy at some ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ), ... of a Phase 2a clinical trial evaluating,MAP0005 ... chronic obstructive,pulmonary disease (COPD). MAP0005 is ... long-acting,beta2-agonist delivered to the respiratory tract using ...
... BPUR ) announced today that the trading symbol for ... BPUR at the open of the market on,Wednesday, October ... revert to the following ticker symbols: BPREW reverting to ... Biopure Corporation Biopure Corporation develops, manufactures and ...
... HRAL) announced today that it has formed an alliance ... Stores (NYSE: WMT ) to help,conquer hearing loss ... Starting November 15, 2007, HearAtLast customers will receive a,$100.00 ... with,their American Express card. The promotion is scheduled to ...
Cached Medicine News:Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Threshold for bowel surgery may be too high, warn experts 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... 10, 2014  Breg, Inc., a premier provider ... the FreeRunner™ knee brace with new innovations to ... mal-tracking return to active lifestyles.  FreeRunner,s patent-pending design ... providing support when patients need it most, and ... Patellofemoral issues are the most common ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SPRING, Md., Nov. 19, 2010 Xanodyne Pharmaceuticals ... version of the prescription pain medication propoxyphene, has ... at the request of the U.S. Food and ... manufacturers of Xanodyne,s decision and they will be ...
... Inc., (NYSE: HRC ) invites you to ... Piper Jaffray Health Care Conference in New York City ... You are invited to listen to the ... or access it directly at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=HRC&item_id=3494592 . ...
Cached Medicine Technology:Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market 2Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market 3
... 1064 DW with the capability of emission at ... increased coagulative and ablative capacities.Smart 1064 DW is ... different wavelengths: ordinary 1064 nm (with powers selectable ... (with powers among 2 and 25 W). This ...
... CO2 system was expressly designed to obtain ... A special source and an equally special ... create particular high energy impulses with constant ... as 'top-flat shaped') allow storage of enough ...
... the ideal instrument for safe, repeatable tissular ... majority of surface lesions can be treated, ... scar tissue, with a minimum of heat ... elimination of anaesthetics, risks and adverse side ...
... laser system with CW intensities of up ... all therapeutic application in modern and efficient ... in super-pulsed mode, designed for even the ... also capable of supplying soft laser pulses ...
Medicine Products: